
Sign up to save your podcasts
Or
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
3.7
5353 ratings
This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor.
In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.
131 Listeners
323 Listeners
160 Listeners
863 Listeners
496 Listeners
274 Listeners
3,318 Listeners
86 Listeners
135 Listeners
1,084 Listeners
39 Listeners
186 Listeners
351 Listeners
424 Listeners
34 Listeners